It seemed like you were talking about getting the

It seemed like you were talking about getting the GNBT S-1 approved...

Here are my thoughts:

I believe the NGIO spin capital plan COULD have a material effect on the SP and be helpful in getting access to the GNBT S-1 funding. If the market sees that there is a valid valuation for NGIO that is actually going to add "100s of millions" to the GNBT balance sheet, we may have a reaction. Unfortunately, that may or may not stick on the OTC. We may need the actual spin, which is still sounding like end of fiscal Q (end of April).

With our current info, I don't believe we can count on much out of China in that time frame.

So that leaves the following potential short-term drivers (2 months), in my mind:

1) The 10-Q in two weeks - will it have something to hang our hats on? Kind of doubt it.

2) An Excellagen licensing deal. No word on that for a month. Maybe there's a surprise coming?

3) New news out of China.

4) Totally new news from one of the other subsidiaries that revenue is somehow being driven.


Not a banner crop of things to propel us in the next 2 months, IMO. Joe may have to work some miracles again on extending deals, etc., if the SP doesn't bite on the announcement of the NGIO spin details.

So let's have those NGIO spin details and see what happens!